Finding the genes behind X-linked dystonia-parkinsonism
Assembling the Genetic Architecture of X-linked Dystonia Parkinsonism
This project looks for specific genetic changes linked to X-linked dystonia-parkinsonism and explores laboratory approaches to correct those changes for people affected by the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11285328 on NIH RePORTER |
What this research studies
From a patient perspective, the team is comparing genomes and RNA from affected people to pinpoint the DNA change that disrupts the TAF1 gene and harms striatal neurons. They use patient-derived neural stem cells and induced neurons to study how an SVA insertion and a variable hexamer repeat change RNA splicing and reduce TAF1 expression. In lab models, removing the SVA with CRISPR rescued the transcriptional problems, and the renewed work will test antisense oligonucleotides (ASOs) to modulate TAF1. The goal is to turn these molecular findings into strategies that could eventually be developed into treatments.
Who could benefit from this research
Good fit: Ideal candidates are people with genetically confirmed X-linked dystonia-parkinsonism (TAF1 SVA-associated mutations) or family members willing to provide samples for genetic and cellular studies.
Not a fit: People whose movement disorder is caused by other genes or who lack the TAF1 SVA mutation, or those with very advanced disease, may not receive direct benefit from this research.
Why it matters
Potential benefit: If successful, this work could lead to therapies that restore normal TAF1 function and slow or prevent neuron loss in people with XDP.
How similar studies have performed: Laboratory studies using patient-derived cells have shown that CRISPR removal of the SVA and early ASO approaches can reverse molecular defects, but clinical benefit in people has not yet been demonstrated.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Talkowski, Michael E — Massachusetts General Hospital
- Study coordinator: Talkowski, Michael E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.